However, the combined sensitivity for our previously reported marker panel (HOXA9 + HIC1) was 88.9% with 100% specificity, achieving an AUC of 0.95 for differentiating serum samples of patients with EOC from normal control samples, thereby reflecting as the best discriminatory marker panel for non-invasive detection of EOC cancer using serum cell-free DNA (Table 2 and Figure 6). Here, HOXA9 is linked to cancer.